31272512|t|Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum.
31272512|a|BACKGROUND: Neuropathological studies have linked tau aggregates to neuronal loss. To describe the spatial distribution of neurofibrillary tangle pathology in post-mortem tissue, Braak staging has been used. The aim of this study was to examine in vivo associations between tau pathology, quantified with [18F]flortaucipir PET in regions corresponding to Braak stages, and atrophy across the Alzheimer's disease (AD) spectrum. METHODS: We included 100 subjects, including 58 amyloid-beta positive patients with mild cognitive impairment (MCI, n = 6) or AD dementia (n = 52) and 42 controls with subjective cognitive decline (36% amyloid-beta positive). All subjects underwent a dynamic [18F]flortaucipir PET to generate non-displaceable binding potential (BPND) maps. We extracted average [18F]flortaucipir BPND entorhinal, Braak III-IV (limbic) and Braak V-VI (neocortical) regions of interest (ROIs). T1-weighted MRI was used to assess gray matter (GM) volumes. We performed linear regression analyses using [18F]flortaucipir BPND ROIs as independent and GM density (ROI or voxelwise) as dependent variable. RESULTS: In MCI/AD subjects (age [mean +- SD] 65 +- 8 years, MMSE 23 +- 4), [18F]flortaucipir BPND was higher than in controls (age 65 +- 8, MMSE 29 +- 1) across all ROIs (entorhinal 0.06 +- 0.21 vs 0.46 +- 0.25 p < 0.001, Braak III-IV 0.11 +- 0.10 vs 0.46 +- 0.26, p < 0.001, Braak V-VI 0.07 +- 0.07 vs 0.38 +- 0.29, p < 0.001). In MCI/AD, greater [18F]flortaucipir BPND in entorhinal cortex was associated with lower GM density in medial temporal lobe (beta - 0.40, p < 0.001). Greater [18F]flortaucipir BPND in ROI Braak III-IV and Braak V-VI was associated with smaller GM density in lateral and inferior temporal, parietal, occipital, and frontal lobes (range standardized betas - 0.30 to - 0.55, p < 0.01), but not in medial temporal lobe (beta - 0.22, p 0.07). [18F]Flortaucipir BPND in ROI Braak I-II was not associated with GM density loss anywhere. When quantifying [18F]flortaucipir BPND across brain lobes, we observed both local and distant associations with GM atrophy. In controls, there were no significant associations between [18F]flortaucipir BPND and GM density (standardized betas ranging from - 0.24 to 0.02, all p > 0.05). CONCLUSIONS: In MCI/AD patients, [18F]flortaucipir binding in entorhinal, limbic, and neocortical regions was associated with cortical atrophy.
31272512	34	51	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	52	55	tau	Gene	4137
31272512	64	71	atrophy	Disease	MESH:D001284
31272512	83	102	Alzheimer's disease	Disease	MESH:D000544
31272512	163	166	tau	Gene	4137
31272512	181	194	neuronal loss	Disease	MESH:D009410
31272512	236	258	neurofibrillary tangle	Disease	MESH:D055956
31272512	387	390	tau	Gene	4137
31272512	418	435	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	486	493	atrophy	Disease	MESH:D001284
31272512	505	524	Alzheimer's disease	Disease	MESH:D000544
31272512	526	528	AD	Disease	MESH:D000544
31272512	588	600	amyloid-beta	Gene	351
31272512	610	618	patients	Species	9606
31272512	629	649	cognitive impairment	Disease	MESH:D003072
31272512	651	654	MCI	Disease	MESH:D060825
31272512	666	677	AD dementia	Disease	MESH:D000544
31272512	719	736	cognitive decline	Disease	MESH:D003072
31272512	742	754	amyloid-beta	Gene	351
31272512	799	816	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	869	873	BPND	Disease	
31272512	902	919	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	920	924	BPND	Disease	
31272512	1123	1140	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	1141	1145	BPND	Disease	
31272512	1235	1238	MCI	Disease	MESH:D060825
31272512	1239	1241	AD	Disease	MESH:D000544
31272512	1299	1316	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	1317	1321	BPND	Disease	
31272512	1556	1559	MCI	Disease	MESH:D060825
31272512	1560	1562	AD	Disease	MESH:D000544
31272512	1572	1589	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	1590	1594	BPND	Disease	
31272512	1711	1728	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	1729	1733	BPND	Disease	
31272512	1991	2008	[18F]Flortaucipir	Chemical	MESH:C000591008
31272512	2009	2013	BPND	Disease	
31272512	2099	2116	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	2117	2121	BPND	Disease	
31272512	2195	2205	GM atrophy	Disease	MESH:D002549
31272512	2267	2284	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	2285	2289	BPND	Disease	
31272512	2385	2388	MCI	Disease	MESH:D060825
31272512	2389	2391	AD	Disease	MESH:D000544
31272512	2392	2400	patients	Species	9606
31272512	2402	2419	[18F]flortaucipir	Chemical	MESH:C000591008
31272512	2495	2511	cortical atrophy	Disease	MESH:D001284
31272512	Association	MESH:C000591008	MESH:D003072
31272512	Association	MESH:C000591008	MESH:D001284
31272512	Association	MESH:D003072	351
31272512	Association	MESH:C000591008	MESH:D000544
31272512	Association	MESH:D001284	4137
31272512	Association	MESH:C000591008	4137
31272512	Association	MESH:D060825	351
31272512	Association	MESH:D000544	351
31272512	Association	MESH:C000591008	MESH:D060825
31272512	Association	MESH:C000591008	MESH:D002549
31272512	Association	MESH:D000544	4137
31272512	Association	MESH:D009410	4137

